MINNEAPOLIS, Sept. 14, 2021 /PRNewswire/ — Daikin Applied today introduced the upgraded Rebel Applied™ with enVerid Sorbent Ventilation Technology™ (SVT), the industry’s first packaged total-air-quality system that combines the benefits of sorbent media with a class-leading, configurable rooftop unit. Read more...
Read More“For business executives in the Gulf like myself who have enjoyed friendships and business relationships with Israelis for many years, the Abraham Accords signed a year ago opened a new market,” writes Dr. Sabah al-Binali, GCC Venture Capital Partner and Head of the Gulf Region for OurCrowd. “Many Emiratis have spent time studying or working in the United States or Europe and our connections with Jewish and Israeli colleagues go back a long time. The Abraham Accords between the UAE and Israel gave us a chance to explore the opportunities arising from those relationships.” The UAE “has deep business connections in Africa and Southeast Asia and it makes sense for OurCrowd to use the UAE as a base from which to reach these regions. We aim to become a twin to OurCrowd HQ in Israel, providing the same services, the same investments, the same support to start-ups in Africa and the Eastern Hemisphere, mirroring the success of OurCrowd’s existing business in Israel, Europe and North America. We can also be a gateway to the wider world,” al-Binali writes...
Read MoreVENTURA, Calif.–(BUSINESS WIRE)–Nexa3D, the maker of ultrafast polymer 3D printers, today announced the launch of its next generation membrane, Everlast-2 at RAPID + TCT 2021. Those attending the event, from September 13 to 15 at McCormick Place, Chicago, will be able to view the new Everlast-2 membrane in action and learn about its key features alongside Nexa3D’s expanding portfolio of ultrafast 3D printing products. Attendees can visit Nexa3D on booth E7428. Read...
Read MoreBINYAMINA, Israel, Sept. 13, 2021 /PRNewswire/ — OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients. The signature was discovered using OncoHost’s first-of-its-kind, AI-based platform, PROphet®, and the study will be presented as a poster at the ESMO Virtual Congress 2021. Read...
Read MoreLONDON, Sept 13 (Reuters) – Europe’s largest frozen food group and the maker of Birds Eye fish fingers has teamed-up with U.S. company BlueNalu to develop seafood products grown from cells in a laboratory rather than harvested from the oceans. Read...
Read More
